Experts In Vasectomy and Urological Treatments

Dr. Snoy is a general urologist. In addition to vasectomies he also treats:
• Bladder control
• Overactive bladder
• Bladder cancer
• Urinary incontinence
• Kidney stones
• Prostate disorders
• Prostate cancer
• Erectile dysfunction

Incontinence and Bladder Studies


Study: Vicinium

Efficacy testing of Vicinium in bladder cancer patients previously treated with BCG.

Indication:

Bladder Cancer

Key Points:

Study is open label, so all eligible patients receive medication.

Who?

Recurrence with higher grades TCCa after 5 induction BCG and 2 maintenance BCG.

 

Study: Spectrum

 

Study of Surgical adjuvant post-operative to TURBT

Indication:

Bladder Cancer

Key Points:

Eligible patients may receive medication or placebo.

Who?

Patients who have low grade bladder tumors with negative cytology.

 

Study: Ipsen

Evaluating Dysport for the treatment of urinary incontinence in subjects with neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis

Indication:

Urinary Incontinence

Key Points:

Eligible patients may receive either medication or placebo initially for 1st treatment, but receive the medication 12 weeks after the first treatment.

Who?

MS or SCI, on SIC with persistent incontinence despite OAB meds (antimuscarinic or β-3 agonists).

 

Study: Adelphi

Pain and quality of life survey of individuals with advanced bladder cancer

Indication:

Bladder Cancer

Key Points:

Observational study

Who?

Advanced bladder cancer: metastatic, node progression or T4b, or patients being sent for chemotherapy or radiation.

 

Study: Aquinox

Efficacy and safety of AQX-1125 (oral tablet) in reducing bladder pain from Interstitial cystitis

Indication:

Interstitial Cystitis (IC)

Key Points:

Eligible patient may receive medication or placebo

Who?

Bladder pain and interstitial cystitis. Experiencing moderate to severe symptoms.

 

Study: Astellas

Evaluating a drug (myrbetriq) for OAB in patients with BPH who are already taking tamsulosin

Indication:

Overactive Bladder & Benign Prostatic Hyperplasia (BPH)

Key Points:

Patient may receive myrbetriq or placebo.

Who?

Men with BPH and persistent OAB despite taking tamsulosin.

 

View other current clinical trials